Latest News

GW Pharma announces Home Office Rescheduling

Easing restrictions in the UK

The United Kingdom has eased restrictions on Epidyolex, placing it on the lowest level of control. The cannabis-based medicine is moving from Schedule 2 to a Schedule 5 under the Misuse of Drugs Regulations 2001.

This move will take effect immediately throughout the United Kingdom, with Northern Ireland enacting separate legislation.

“The decision to move Epidyolex to a low level of control is an important one for patients, their families, health-care professionals, pharmacists and the NHS as a whole – reducing costs and ensuring the medicine can be dispensed more easily,” Chris Tovey, GW Pharma’s COO, stated in a press release.

Also Read:  Is CBD oil legal in the UK? The UK’s CBD law explained

Down scheduling

Epidyolex is an oral solution containing highly purified cannabidiol or CBD. It received approval in 2019 for treatment of seizure relating to Dravet syndrome or Lennox-Gastaut syndrome (LGS).

It is available in the U.S. under the name Epidiolex. In 2018, it was removed entirely from the controlled substance list in the United States.

Also Read:  CBD oil for epilepsy – Can it help with seizures?

Low risk, big reward

In making their decision, the advisory council cited the “low risk of abuse potential, low-risk dependency and low risk of diversion.”

GW Pharma’s medicines are now free from all controlled drug requirements. This means that patients will have greater freedom and flexibility on their medications and repeat prescriptions.

The pharmaceutical company are now in a strong stock position with all analysts rating the stock a buy.

RELATED: FSD Pharma swaps cannabis for COVID

Also Read:  Why is the Portuguese government obstructing hemp production?

Jon Cosgrave

Jon is a content writer and copywriter. When not grappling with words, he grapples at jiu-jitsu. His fingers are in constant agony.

Related Articles

Leave a Reply

Back to top button